Medical Tidbits, Pfizer Partners with Breast Cancer Leaders to Chronicle the Lives of Women with Metastatic Breast Cancer



Pfizer Inc., in partnership with five leading breast cancer advocacy organizations, today announced the next chapter of the Breast Cancer: A Story Half Told initiative, launched in 2014 to identify public misperceptions and gaps in knowledge surrounding metastatic breast cancer (MBC), the most advanced form of breast cancer. Research conducted as part of this initiative revealed that the majority of Americans (60%) reported they know little to nothing about MBC.1 The new chapter aims to address this lack of understanding through the perspectives of women living with MBC, as chronicled by prominent photographers. – See more at: read more

Heart failure treatment (Pr)ENTRESTO(TM) (LCZ696) shown to reduce the risk of cardiovascular death and hospitalization(1) approved by Health Canada 

DORVAL, QC, Oct. 6, 2015 /CNW/ – ENTRESTO™ (sacubitril/valsartan), previously known as LCZ696 has been approved by Health Canada for the treatment of heart failure with reduced ejection fraction (HFrEF) in patients with NYHA Class II or III, to reduce the incidence of cardiovascular death and heart failure hospitalization. The approval of the Novartis treatment is based on results from the 8,442-patient PARADIGM-HF study which was stopped early when it showed ENTRESTO™ significantly reduced the incidence of cardiovascular death versus ACE-inhibitor enalapril, a standard of care treatment. read more

3M Drug Delivery Systems and Impel NeuroPharma Form a Strategic Alliance

ST. PAUL, Minn. & SEATTLE–(EON: Enhanced Online News)–3M Drug Delivery Systems (3M) and Impel NeuroPharma Inc (Impel) today announced a strategic alliance aimed at advancing Impel’s revolutionary Precision Olfactory Delivery (POD) technology for the enhanced Central Nervous System (CNS) delivery of drug products. The alliance further solidifies 3M’s presence as a clear leader in the drug delivery sector and shows its continued commitment to cutting-edge technology. read more

Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Prostate Cancer Study  

CALGARY, Oct. 6, 2015 /PRNewswire/ – Oncolytics Biotech® Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN® in patients with recurrent or metastatic castration resistant prostate cancer (IND 209). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen’s University in Kingston, Ontario. read more

Acutus Medical’s AcQMap™ High Resolution Imaging and Mapping System Provides High-Resolution Cardiac Mapping Combined with Exceptional Accuracy in Ultrasound Chamber Reconstruction in Patients with Atrial Fibrillation

SAN DIEGO–(BUSINESS WIRE)–Acutus Medical, a global heart rhythm technology company, today presented data that demonstrated the ability of the AcQMap™ High Resolution Imaging and Mapping System to precisely overlay high-resolution dipole density (source charge) signals on an accurate ultrasound-based reconstruction of the left atrial chamber. The AcQMap system was able to provide a clearer picture of the patient’s heart rhythm. The initial study findings were presented during an oral presentation at the 10th annual Heart Rhythm Congress held in Birmingham, United Kingdom (UK) from October 4-7, 2015.  read more

Illumina Expands Use of HiSeq X™ Sequencing System to Include Non-Human Species

October 06, 2015 06:30 AM Eastern Daylight Time

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ:ILMN) today announced it has expanded the rights of use for the HiSeq X Sequencing System to allow customers to perform whole-genome sequencing of non-human species. The updated rights of use will take effect immediately for existing customers of the HiSeq X Ten and HiSeq X Five, and will apply to all new customers of the sequencing systems. read more

Alvogen Acquires Five Hormonal Products in Russia and CIS

PINE BROOK, N.J.–(BUSINESS WIRE)–Alvogen, today announced that it has acquired five hormonal branded products from Bayer Pharma AG in Russia and CIS.  read more

Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, proudly congratulates William C. Campbell, a retired scientist from Merck Research Laboratories, who was jointly named the 2015 Nobel Prize winner in Physiology or Medicine with Satoshi Omura for the discovery of avermectin, which led to Merck’s development of Mectizan (ivermectin), a treatment for river blindness (also known as onchocerciasis) in Africa, Latin America and Yemen. They will share the prize with Youyou Tu for her discoveries concerning a novel therapy against malaria. read more



Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.